The economics of medical therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia

Wei JT, Calhoun E, Jacobsen SJ: Urologic disease in America project: benign prostatic hyperplasia. J Urol 2005, 173:1256–1261. An important analysis of the annual costs of medical therapy for BPH.

Chapple CR: Selective 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996, 29:129–144.

MacDonald D, McNicholas TA: Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life. Drugs 2003, 63:1947–1962.

Carbone DJ Jr, Hodges S: Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 2003, 15:299–306.

McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398. The largest, longest, most important clinical trial undertaken by a nonpharmaceutical research group to determine the long-term effects of medical therapy for BPH.

AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003, 170:530–547. This most recent update of the 1994 BPH guidelines critically examines and analyzes the data from all clinical trials available to provide guidelines for the management of BPH based on best available evidence.

Chrischilles E, Rubenstein L, Chao J, et al.: Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. Clin Ther 2001, 23:727–743.

Hillman AL, Schwartz JS, Willian MK, et al.: The costeffectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology 1996, 47:169–178.

Berges RS: Impact of therapy used in clinical practice on lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) disease progression. Eur Urol 2003, 2(suppl):19–24.

de la Rosette JJ, Kortman BB, Rossi C, et al.: Long-term risk of re-treatment of patients using-blockers for lower urinary tract symptoms. J Urol 2002, 167:1734–1739.

Ohsfeldt RL, Kreder KJ, Klein RW, Chrischilles EA: Costeffectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia. J Manag Care Pharm 2004, 10:412–422.

Nickel JC: Comparison of clinical trials with finasteride and dutasteride. Rev Urol 2004, 6(suppl 9):31–39.

Cockrum PC, Finder SF, Ries AJ, Potyk RP: A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia. Pharmacoeconomics 1997, 11:550–565.

Baladi JF, Menon D, Otten N: An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics 1996, 9:443–454.

McConnell JD, Bruskewitz R, Walsh P: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998, 338:557–563.

McDonald H, Hux M, Brisson M, et al.: An economic evaluation of doxazosin, finasteride, and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol 2004, 11:2327–2340. A comprehensive assessment employing a semi-Markov decision analytical model of the costs and cost-utility (QALY gained) for finasteride and combination therapy employing data from PLESS (reference 15) and MTOPS (reference 5).

Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992, 146:473–481.

Roehrborn CG, Boyle P, Bergner D, et al.: Serum prostatespeci fic antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a 4-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999, 54:662–669.

Roehrborn CG, McConnell JD, Bonilla J, et al.: Serum prostate-specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR Long-term Efficacy and Safety Study. J Urol 2000, 163:13–20.

Roehrborn CG, Malde M, Cook TJ, et al.: Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001, 58:210–216.

Albertsen PC, Pellissier JM, Lowe FC, et al.: Economic analysis of finasteride: a model-based approach using data from the Proscar Long-term Efficacy and Safety Study. Clin Ther 1999, 21:1006–1024.

Baldwin KC, Ginsberg PC, Roehrborn CG, Harkaway RC: Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology 2001, 58:203–209.

Barkin J, Guimaraes M, Jacobi G, et al.: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha-reductase inhibitor dutasteride. Eur Urol 2003, 44:461–466.

Jepsen JV, Bruskewitz RC: Surgical and nonsurgical invasive treatment of benign prostatic hyperplasia. Drugs Today (Barc) 1998, 34:353–360.

Blute M, Ackerman SJ, Rein AL, et al.: Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia. Part II: results. Urology 2000, 56:981–987.

Jepsen JV, Bruskewitz RC: Economics of transurethral thermotherapy of the prostate. World J Urol 1998, 16:138–141.

Naslund MJ, Carlson AM, Williams MJ: A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period. J Urol 2005, 173:2090–2093.